On this basis a comparative assessment of the malignant behaviour of PCa cells treated with combined HDAC-blockade, mTOR-inhibitor and low dosed IFNα, as opposed to each single agent, was performed. The gene discussed is HDAC9; the disease is posterior cortical atrophy.